Cetrorelix vs Ganirelix

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicCetrorelixGanirelix
What it is

A synthetic analogue of GnRH with amino acids changed at five positions, which blocks rather than activates the GnRH receptor, according to the label.1

A synthetic decapeptide derived from natural GnRH with amino acids changed at six positions, giving it strong GnRH-blocking activity, according to the label.3

FDA status

FDA-approved

FDA-approved as Cetrotide for use in controlled ovarian stimulation1,2

FDA-approved. Drugs@FDA lists Cetrotide with an original approval date of August 11, 2000. The cited label has no boxed warning.1,2

Is cetrorelix FDA-approved?

FDA-approved

FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation3,4

FDA-approved. Drugs@FDA lists Organon’s ganirelix acetate, NDA 021057, with an original approval date of July 29, 1999. The cited label has no boxed warning.3,4

Is ganirelix FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

Not among the six peptides the policy lists.5

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Two adequate and well-controlled Phase 3 studies with active comparators in women undergoing controlled ovarian stimulation, described in the label.1
  • Small, short, or incompletely reported human study A third, non-comparative Phase 3 study in 303 women, described in the label.1

Large randomized human trials

  • Large randomized human trial Protocol 38602: a multicenter, double-blind, randomized study in 332 participants, women undergoing ovarian hyperstimulation for IVF, described in the label as one of the two studies establishing its effectiveness.3
  • Large randomized human trial Protocol 38607: a multicenter, open-label, randomized study in which 463 participants received ganirelix, with a GnRH agonist as the reference treatment, described in the label.3
Records collected

26 ClinicalTrials.gov records and 22 PubMed records collected

27 ClinicalTrials.gov records and 6 PubMed records collected

Area of study

Hormones, Sexual and reproductive health1

Hormones, Sexual and reproductive health3

Latest dated events
  1. DailyMed publishes the Cetrotide label version cited on this page.1
  2. FDA approves Cetrotide, according to Drugs@FDA.2
  1. DailyMed publishes the ganirelix label version cited on this page.3
  2. FDA approves Organon’s ganirelix acetate, according to Drugs@FDA.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026